West Pharmaceutical Services, Inc. - 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2005. West Pharmaceutical Services, Inc. is a global manufacturer of pharmaceutical packaging components and medical device solutions. The reporting period is significantly impacted by the acquisition of Tech Group, Inc. on May 20, 2005, which led to the establishment of two new reportable segments: "Pharmaceutical Systems" and "Tech including the West Device Group."
Key Financial Metrics
(All figures in thousands, except per share data)
| Metric | Three Months Ended 6/30/05 | Six Months Ended 6/30/05 |
|---|---|---|
| Net Sales | $173,000 | $322,400 |
| Gross Profit | $50,600 | $97,000 |
| Gross Margin | 29.2% | 30.1% |
| Operating Profit | $19,900 | $40,000 |
| Net Income | $12,800 | $26,100 |
| Diluted EPS (Continuing Ops) | $0.38 | $0.79 |
| Cash from Operations (6mo) | $29,000 | |
| Total Debt | $278,000 (as of 6/30/05) | |
| Working Capital | $142,500 (as of 6/30/05) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 27.1% for the quarter and 20.9% year-to-date compared to 2004. The Tech acquisition contributed $17.5 million to the sales increase in both periods. Excluding Tech, organic sales grew 14.2% in the quarter.
- Profitability: Net income rose 66.2% for the quarter and 77.6% year-to-date. This was driven by higher sales volume and a $1.4 million restructuring credit related to a U.K. facility closure.
- Margins: Gross margin declined to 29.2% (Q2) and 30.1% (YTD) from 31.1% and 30.7% in the prior year, respectively. This compression is attributed to the inclusion of the Tech business, which carries lower margins (15-20% for molded plastics) compared to the core pharmaceutical systems business.
- Debt and Liquidity: Total debt increased to $278 million from $160.8 million at year-end 2004, primarily to finance the Tech acquisition. Borrowings under the revolving credit facility rose to $177 million. Cash and equivalents decreased to $61.5 million.
Guidance, Outlook, and Risks
- Acquisitions: The company completed the $140 million acquisition of Tech Group, Inc. Subsequently, on August 2, 2005, it acquired 90% of Medimop Medical Projects, Ltd. for approximately $36.25 million (cash and stock).
- Financing: On July 28, 2005, the company issued $75 million in senior floating rate notes to fund the Medimop acquisition and reduce revolving credit borrowings. Interest rates were effectively fixed via swap agreements at 5.32% and 5.51%.
- Capital Spending: Full-year 2005 capital spending is projected at approximately $60 million, including spending in the acquired Tech business.
- Discontinued Operations: The company sold its drug delivery business in Q1 2005. The clinical services unit remains as a discontinued operation pending sale.
- Risks: Key risks include the successful integration of acquired businesses, raw material price escalation (petroleum-based), foreign currency fluctuations, and the commercial success of customer products. The company is also a defendant in lawsuits related to a 2003 plant explosion, though management believes reserves are sufficient.
Investor Verification Checklist
- Acquisition Integration: Verify the progress of integrating Tech Group and Medimop, specifically regarding the realization of projected synergies and the impact on future margins.
- Debt Covenants: Confirm continued compliance with the amended leverage ratio covenant (3.5x EBITDA) following the increased debt load from recent acquisitions.
- Discontinued Operations: Monitor the timeline and terms for the potential sale of the remaining clinical services business.
- Stock-Based Compensation: Review the ongoing impact of SFAS 123(R) adoption on future earnings, as the company now recognizes fair-value based expenses for stock options and awards.
- Raw Material Costs: Assess the company's ability to pass on increased petroleum-based raw material costs to customers without impacting volume.